A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

NCT03129100 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

773

Enrollment

INDUSTRY

Sponsor class

Conditions

Axial Spondyloarthritis

Interventions

DRUG: Ixekizumab
DRUG: Placebo

Sponsor

Eli Lilly and Company